Xinnoway: Subsidiary receives $420 million upfront payment from AstraZeneca
Xinnuowei's subsidiary, Jushi Bio, has received a $420 million upfront payment from AstraZeneca as part of a strategic collaboration. This partnership focuses on the discovery of novel peptide molecules and the development of long-acting delivery products. The agreement signifies a significant milestone for Jushi Bio and its entry into a broader strategic alliance with AstraZeneca. AI
IMPACT This collaboration may lead to advancements in drug discovery and delivery, potentially impacting the pharmaceutical AI sector.